The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background The efficacy of combined modality therapy is evaluated for patients with extensive-stage (ES) small cell lung cancer (SCLC). This study evaluated prognostic factors affecting the risk of thoracic progression in ES-SCLC patients likely to undergo thoracic radiotherapy combined chemotherapy. Methods A retrospective review of ES-SCLC patients who had received systemic chemotherapy at our...
1,2,3,4,5,6,7,10-Octahydro-5-hydroxy-1,5-imino-3-benzazocin-4,7,10-trione (3a) was synthesized from the hexahydro-1,5-imino-9-methoxy-3,8,11-trimethyl-4-oxo-3-benzazocine (4a) in six steps and evaluated for its antitumor activity against L1210 in vitro.
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.